Signaling by Leptin (Homo sapiens)

From WikiPathways

Jump to: navigation, search
1, 3, 7, 11, 12, 15...14, 39492, 8, 10, 4943476, 3843104314, 4013, 28, 53-55104910, 14, 30, 41, 51...109, 26cytosolnucleoplasmATPSH2B1-2 ATPLEP:p-LEPR:p-JAK2:p-STAT5LEP SH2B1-2 SOCS3 p-Y699-STAT5B IRS2 SH2B1-2p-STAT5A, p-STAT5Bp-12Y-JAK2 LEP p-STAT5 dimerLEP IRS1 p-12Y-JAK2 ATPIRS2 STAT5A LEP:p-LEPR:p-JAK2p-Y705-STAT3 LEP p-Y986,Y1079,Y1141-LEPR-1 LEPR:JAK2LEPp-Y986,Y1079,Y1141-LEPR-1 p-Y699-STAT5B p-Y705-STAT3 dimerLEP p-STAT5 dimerADPp-12Y-JAK2 ATPIRS1,2LEP:p-LEPR:p-JAK2:SH2B1:IRS1,2p-12Y-JAK2 STAT5B RAF/MAP kinasecascadeLEP p-12Y-JAK2 LEP:p-LEPR:p-JAK2:STAT5ADPp-Y694-STAT5A STAT5A,STAT5BADPLEP:p-LEPR:p-JAK2:SHP2ADPLEP:p-LEPR:p-JAK2:p-SHP2p-Y986,Y1079,Y1141-LEPR-1 LEP LEP p-Y699-STAT5B p-Y986,Y1079,Y1141-LEPR-1 IRS1 LEP p-Y705-STAT3 ADPLEPR-1 p-Y-IRS2 LEP:LEPR:p-JAK2p-Y986,Y1079,Y1141-LEPR-1 p-Y694-STAT5A LEP p-Y705-STAT3 LEP:p-LEPR:p-JAK2:SH2B1STAT5B ADPp-Y986,Y1079,Y1141-LEPR-1 LEP:p-LEPR:p-JAK2:SOCS3LEP:p-LEPR:p-JAK2:STAT3ATPp-Y694-STAT5A LEPR-1 LEP:p-LEPR:p-JAK2:p-STAT3LEP JAK2 PTPN11 PTPN11LEP p-Y694-STAT5A p-12Y-JAK2 LEP:LEPR:JAK2SOCS3p-Y705-STAT3 dimerp-12Y-JAK2 LEP:p-LEPR:p-JAK2:SH2B1:p-IRS1,2p-12Y-JAK2 p-Y986,Y1079,Y1141-LEPR-1 p-12Y-JAK2 JAK2 STAT3 STAT5A LEPR-1 p-Y986,Y1079,Y1141-LEPR-1 p-Y546,Y584-PTPN11 ATPp-12Y-JAK2 p-12Y-JAK2 p-Y986,Y1079,Y1141-LEPR-1 p-Y986,Y1079,Y1141-LEPR-1 p-12Y-JAK2 p-Y-IRS1 STAT3SH2B1-2 p-Y986,Y1079,Y1141-LEPR-1 p-Y705-STAT3LEP p-Y699-STAT5B 2, 49102, 492, 49102, 492, 492, 491045, 462, 492, 492, 494, 5, 19, 21, 22, 25...102, 4945, 462, 49


Description

Leptin (LEP, OB, OBS), a circulating adipokine, and its receptor LEPR (DB, OBR) control food intake and energy balance and are implicated in obesity-related diseases (recently reviewed in Amitani et al. 2013, Dunmore and Brown 2013, Cottrell and Mercer 2012, La Cava 2012, Marroqui et al. 2012, Paz-Filho et al. 2012, Denver et al. 2011, Lee 2011, Marino et al. 2011, Morton and Schwartz 2011, Scherer and Buettner 2011, Shan and Yeo 2011, Wauman and Tavernier 2011, Dardeno et al. 2010, Bjorbaek 2009, Morris and Rui 2009, Myers et al. 2008), including cancer (Guo et al. 2012), inflammation (Newman and Gonzalez-Perez 2013, Iikuni et al. 2008), and angiogenesis (Gonzalez-Perez et al. 2013).
The identification of spontaneous mutations in the leptin gene (ob or LEP) and the leptin receptor gene (Ob-R, db or LEPR) genes in mice opened up a new field in obesity research. Leptin was discovered as the product of the gene affected by the ob (obesity) mutation, which causes obesity in mice. Likewise LEPR is the product of the gene affected by the db (diabetic) mutation. Leptin binding to LEPR induces canonical (JAK2/STATs; MAPK/ERK 1/2, PI-3K/AKT) and non-canonical signaling pathways (PKC, JNK, p38 MAPK and AMPK) in diverse cell types. The binding of leptin to the long isoform of LEPR (OB-Rl) initiates a phosphorylation cascade that results in transcriptional activation of target genes by STAT5 and STAT3 and activation of the PI3K pathway(not shown here), the MAPK/ERK pathway, and the mTOR/S6K pathway. Shorter LEPR isoforms with truncated intracellular domains are unable to activate the STAT pathway, but can transduce signals by way of activation of JAK2, IRS-1 or ERKs, including MAPKs.
LEPR is constitutively bound to the JAK2 kinase. Binding of LEP to LEPR causes a conformational change in LEPR that activates JAK2 autophosphorylation followed by phosphorylation of LEPR by JAK2. Phosphorylated LEPR binds STAT3, STAT5, and SHP2 which are then phosphorylated by JAK2. Phosphorylated JAK2 binds SH2B1 which then binds IRS1/2, resulting in phosphorylation of IRS1/2 by JAK2. Phosphorylated STAT3 and STAT5 dimerize and translocate to the nucleus where they activate transcription of target genes (Jovanovic et al. 2010). SHP2 activates the MAPK pathway. IRS1/2 activate the PI3K/AKT pathway which may be the activator of mTOR/S6K.
Several isoforms of LEPR have been identified (reviewed in Gorska et al. 2010). The long isoform (LEPRb, OBRb) is expressed in the hypothalamus and all types of immune cells. It is the only isoform known to fully activate signaling pathways in response to leptin. Shorter isoforms (LEPRa, LEPRc, LEPRd, and a soluble isoform LEPRe) are able to interact with JAK kinases and activate other pathways, however their roles in energy homeostasis are not fully characterized. View original pathway at:Reactome.

Comments

Reactome-Converter 
Pathway is converted from Reactome ID: 2586552
Reactome-version 
Reactome version: 66
Reactome Author 
Reactome Author: May, Bruce

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Dunmore SJ, Brown JE.; ''The role of adipokines in β-cell failure of type 2 diabetes.''; PubMed
  2. White DW, Kuropatwinski KK, Devos R, Baumann H, Tartaglia LA.; ''Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization.''; PubMed
  3. Shan X, Yeo GS.; ''Central leptin and ghrelin signalling: comparing and contrasting their mechanisms of action in the brain.''; PubMed
  4. Turjanski AG, Vaqué JP, Gutkind JS.; ''MAP kinases and the control of nuclear events.''; PubMed
  5. Wellbrock C, Karasarides M, Marais R.; ''The RAF proteins take centre stage.''; PubMed
  6. Rosenthal LA, Winestock KD, Finbloom DS.; ''IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.''; PubMed
  7. Cottrell EC, Mercer JG.; ''Leptin receptors.''; PubMed
  8. Ghilardi N, Skoda RC.; ''The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line.''; PubMed
  9. Ye SK, Agata Y, Lee HC, Kurooka H, Kitamura T, Shimizu A, Honjo T, Ikuta K.; ''The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation.''; PubMed
  10. Bjørbaek C, Uotani S, da Silva B, Flier JS.; ''Divergent signaling capacities of the long and short isoforms of the leptin receptor.''; PubMed
  11. La Cava A.; ''Proinflammatory activities of leptin in non-autoimmune conditions.''; PubMed
  12. Morris DL, Morris DL, Rui L.; ''Recent advances in understanding leptin signaling and leptin resistance.''; PubMed
  13. Hiroike T, Higo J, Jingami H, Toh H.; ''Homology modeling of human leptin/leptin receptor complex.''; PubMed
  14. Li Z, Zhou Y, Carter-Su C, Myers MG, Rui L.; ''SH2B1 enhances leptin signaling by both Janus kinase 2 Tyr813 phosphorylation-dependent and -independent mechanisms.''; PubMed
  15. Marroquí L, Gonzalez A, Ñeco P, Caballero-Garrido E, Vieira E, Ripoll C, Nadal A, Quesada I.; ''Role of leptin in the pancreatic β-cell: effects and signaling pathways.''; PubMed
  16. Gorska E, Popko K, Stelmaszczyk-Emmel A, Ciepiela O, Kucharska A, Wasik M.; ''Leptin receptors.''; PubMed
  17. Newman G, Gonzalez-Perez RR.; ''Leptin-cytokine crosstalk in breast cancer.''; PubMed
  18. Jovanovic Z, Tung YC, Lam BY, O'Rahilly S, Yeo GS.; ''Identification of the global transcriptomic response of the hypothalamic arcuate nucleus to fasting and leptin.''; PubMed
  19. Roskoski R.; ''MEK1/2 dual-specificity protein kinases: structure and regulation.''; PubMed
  20. Wauman J, Tavernier J.; ''Leptin receptor signaling: pathways to leptin resistance.''; PubMed
  21. Kyriakis JM, Avruch J.; ''Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update.''; PubMed
  22. Brown MD, Sacks DB.; ''Protein scaffolds in MAP kinase signalling.''; PubMed
  23. Amitani M, Asakawa A, Amitani H, Inui A.; ''The role of leptin in the control of insulin-glucose axis.''; PubMed
  24. Morton GJ, Schwartz MW.; ''Leptin and the central nervous system control of glucose metabolism.''; PubMed
  25. Roberts PJ, Der CJ.; ''Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.''; PubMed
  26. Stanton ML, Brodeur PH.; ''Stat5 mediates the IL-7-induced accessibility of a representative D-Distal VH gene.''; PubMed
  27. Lee EB.; ''Obesity, leptin, and Alzheimer's disease.''; PubMed
  28. Couturier C, Jockers R.; ''Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers.''; PubMed
  29. Denver RJ, Bonett RM, Boorse GC.; ''Evolution of leptin structure and function.''; PubMed
  30. Martín-Romero C, Sánchez-Margalet V.; ''Human leptin activates PI3K and MAPK pathways in human peripheral blood mononuclear cells: possible role of Sam68.''; PubMed
  31. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS.; ''Leptin in human physiology and therapeutics.''; PubMed
  32. Roskoski R.; ''ERK1/2 MAP kinases: structure, function, and regulation.''; PubMed
  33. Plotnikov A, Zehorai E, Procaccia S, Seger R.; ''The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation.''; PubMed
  34. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR.; ''Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.''; PubMed
  35. Marino JS, Xu Y, Hill JW.; ''Central insulin and leptin-mediated autonomic control of glucose homeostasis.''; PubMed
  36. Roskoski R.; ''RAF protein-serine/threonine kinases: structure and regulation.''; PubMed
  37. McKay MM, Morrison DK.; ''Integrating signals from RTKs to ERK/MAPK.''; PubMed
  38. Gaffen SL, Lai SY, Ha M, Liu X, Hennighausen L, Greene WC, Goldsmith MA.; ''Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity.''; PubMed
  39. Nishi M, Werner ED, Oh BC, Frantz JD, Dhe-Paganon S, Hansen L, Lee J, Shoelson SE.; ''Kinase activation through dimerization by human SH2-B.''; PubMed
  40. Duan C, Li M, Rui L.; ''SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin.''; PubMed
  41. Szanto I, Kahn CR.; ''Selective interaction between leptin and insulin signaling pathways in a hepatic cell line.''; PubMed
  42. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A.; ''Leptin and Inflammation.''; PubMed
  43. Briscoe CP, Hanif S, Arch JR, Tadayyon M.; ''Leptin receptor long-form signalling in a human liver cell line.''; PubMed
  44. Bjørbaek C.; ''Central leptin receptor action and resistance in obesity.''; PubMed
  45. Fantin VR, Sparling JD, Slot JW, Keller SR, Lienhard GE, Lavan BE.; ''Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells.''; PubMed
  46. Kim B, Cheng HL, Margolis B, Feldman EL.; ''Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling.''; PubMed
  47. Bjørbaek C, El-Haschimi K, Frantz JD, Flier JS.; ''The role of SOCS-3 in leptin signaling and leptin resistance.''; PubMed
  48. Paz-Filho G, Mastronardi C, Wong ML, Licinio J.; ''Leptin therapy, insulin sensitivity, and glucose homeostasis.''; PubMed
  49. Carpenter LR, Farruggella TJ, Symes A, Karow ML, Yancopoulos GD, Stahl N.; ''Enhancing leptin response by preventing SH2-containing phosphatase 2 interaction with Ob receptor.''; PubMed
  50. Cseh B, Doma E, Baccarini M.; ''"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.''; PubMed
  51. Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, Cowley MA, Cantley LC, Lowell BB, Elmquist JK.; ''Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice.''; PubMed
  52. Cantwell-Dorris ER, O'Leary JJ, Sheils OM.; ''BRAFV600E: implications for carcinogenesis and molecular therapy.''; PubMed
  53. Luoh SM, Di Marco F, Levin N, Armanini M, Xie MH, Nelson C, Bennett GL, Williams M, Spencer SA, Gurney A, de Sauvage FJ.; ''Cloning and characterization of a human leptin receptor using a biologically active leptin immunoadhesin.''; PubMed
  54. Gonzalez RR, Leavis PC.; ''A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells.''; PubMed
  55. Mistrík P, Moreau F, Allen JM.; ''BiaCore analysis of leptin-leptin receptor interaction: evidence for 1:1 stoichiometry.''; PubMed
  56. Scherer T, Buettner C.; ''Yin and Yang of hypothalamic insulin and leptin signaling in regulating white adipose tissue metabolism.''; PubMed
  57. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.; ''Mutations of the BRAF gene in human cancer.''; PubMed
  58. Cargnello M, Roux PP.; ''Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.''; PubMed
  59. Buettner C, Muse ED, Cheng A, Chen L, Scherer T, Pocai A, Su K, Cheng B, Li X, Harvey-White J, Schwartz GJ, Kunos G, Rossetti L, Buettner C.; ''Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms.''; PubMed
  60. Myers MG, Cowley MA, Münzberg H.; ''Mechanisms of leptin action and leptin resistance.''; PubMed

History

View all...
CompareRevisionActionTimeUserComment
101646view11:51, 1 November 2018ReactomeTeamreactome version 66
101182view21:38, 31 October 2018ReactomeTeamreactome version 65
100708view20:10, 31 October 2018ReactomeTeamreactome version 64
100258view16:56, 31 October 2018ReactomeTeamreactome version 63
99811view15:20, 31 October 2018ReactomeTeamreactome version 62 (2nd attempt)
99355view12:48, 31 October 2018ReactomeTeamreactome version 62
93833view13:39, 16 August 2017ReactomeTeamreactome version 61
93387view11:22, 9 August 2017ReactomeTeamreactome version 61
87176view19:54, 18 July 2016EgonwOntology Term : 'signaling pathway' added !
86473view09:19, 11 July 2016ReactomeTeamreactome version 56
83169view10:15, 18 November 2015ReactomeTeamVersion54
81538view13:04, 21 August 2015ReactomeTeamNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
ADPMetaboliteCHEBI:16761 (ChEBI)
ATPMetaboliteCHEBI:15422 (ChEBI)
IRS1 ProteinP35568 (Uniprot-TrEMBL)
IRS1,2ComplexR-HSA-198273 (Reactome) The proteins mentioned here are examples of IRS family members acting as indicated for IRS.
IRS2 ProteinQ9Y4H2 (Uniprot-TrEMBL)
JAK2 ProteinO60674 (Uniprot-TrEMBL)
LEP ProteinP41159 (Uniprot-TrEMBL)
LEP:LEPR:JAK2ComplexR-HSA-2586512 (Reactome)
LEP:LEPR:p-JAK2ComplexR-HSA-2586521 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1:IRS1,2ComplexR-HSA-2671846 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1:p-IRS1,2ComplexR-HSA-2671844 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1ComplexR-HSA-2671848 (Reactome)
LEP:p-LEPR:p-JAK2:SHP2ComplexR-HSA-2671758 (Reactome)
LEP:p-LEPR:p-JAK2:SOCS3ComplexR-HSA-2672301 (Reactome)
LEP:p-LEPR:p-JAK2:STAT3ComplexR-HSA-2671864 (Reactome)
LEP:p-LEPR:p-JAK2:STAT5ComplexR-HSA-2671867 (Reactome)
LEP:p-LEPR:p-JAK2:p-SHP2ComplexR-HSA-2671749 (Reactome)
LEP:p-LEPR:p-JAK2:p-STAT3ComplexR-HSA-2671874 (Reactome)
LEP:p-LEPR:p-JAK2:p-STAT5ComplexR-HSA-2671835 (Reactome)
LEP:p-LEPR:p-JAK2ComplexR-HSA-2586541 (Reactome)
LEPProteinP41159 (Uniprot-TrEMBL)
LEPR-1 ProteinP48357-1 (Uniprot-TrEMBL)
LEPR:JAK2ComplexR-HSA-2586523 (Reactome)
PTPN11 ProteinQ06124 (Uniprot-TrEMBL)
PTPN11ProteinQ06124 (Uniprot-TrEMBL)
RAF/MAP kinase cascadePathwayR-HSA-5673001 (Reactome) The RAS-RAF-MEK-ERK pathway regulates processes such as proliferation, differentiation, survival, senescence and cell motility in response to growth factors, hormones and cytokines, among others. Binding of these stimuli to receptors in the plasma membrane promotes the GEF-mediated activation of RAS at the plasma membrane and initiates the three-tiered kinase cascade of the conventional MAPK cascades. GTP-bound RAS recruits RAF (the MAPK kinase kinase), and promotes its dimerization and activation (reviewed in Cseh et al, 2014; Roskoski, 2010; McKay and Morrison, 2007; Wellbrock et al, 2004). Activated RAF phosphorylates the MAPK kinase proteins MEK1 and MEK2 (also known as MAP2K1 and MAP2K2), which in turn phophorylate the proline-directed kinases ERK1 and 2 (also known as MAPK3 and MAPK1) (reviewed in Roskoski, 2012a, b; Kryiakis and Avruch, 2012). Activated ERK proteins may undergo dimerization and have identified targets in both the nucleus and the cytosol; consistent with this, a proportion of activated ERK protein relocalizes to the nucleus in response to stimuli (reviewed in Roskoski 2012b; Turjanski et al, 2007; Plotnikov et al, 2010; Cargnello et al, 2011). Although initially seen as a linear cascade originating at the plasma membrane and culminating in the nucleus, the RAS/RAF MAPK cascade is now also known to be activated from various intracellular location. Temporal and spatial specificity of the cascade is achieved in part through the interaction of pathway components with numerous scaffolding proteins (reviewed in McKay and Morrison, 2007; Brown and Sacks, 2009).
The importance of the RAS/RAF MAPK cascade is highlighted by the fact that components of this pathway are mutated with high frequency in a large number of human cancers. Activating mutations in RAS are found in approximately one third of human cancers, while ~8% of tumors express an activated form of BRAF (Roberts and Der, 2007; Davies et al, 2002; Cantwell-Dorris et al, 2011).
SH2B1-2 ProteinQ9NRF2-2 (Uniprot-TrEMBL)
SH2B1-2ProteinQ9NRF2-2 (Uniprot-TrEMBL)
SOCS3 ProteinO14543 (Uniprot-TrEMBL)
SOCS3ProteinO14543 (Uniprot-TrEMBL)
STAT3 ProteinP40763 (Uniprot-TrEMBL)
STAT3ProteinP40763 (Uniprot-TrEMBL)
STAT5A ProteinP42229 (Uniprot-TrEMBL)
STAT5A,STAT5BComplexR-HSA-452094 (Reactome)
STAT5B ProteinP51692 (Uniprot-TrEMBL)
p-12Y-JAK2 ProteinO60674 (Uniprot-TrEMBL)
p-STAT5 dimerComplexR-HSA-507919 (Reactome)
p-STAT5 dimerComplexR-HSA-508012 (Reactome)
p-STAT5A, p-STAT5BComplexR-HSA-507929 (Reactome)
p-Y-IRS1 ProteinP35568 (Uniprot-TrEMBL)
p-Y-IRS2 ProteinQ9Y4H2 (Uniprot-TrEMBL)
p-Y546,Y584-PTPN11 ProteinQ06124 (Uniprot-TrEMBL)
p-Y694-STAT5A ProteinP42229 (Uniprot-TrEMBL)
p-Y699-STAT5B ProteinP51692 (Uniprot-TrEMBL)
p-Y705-STAT3 ProteinP40763 (Uniprot-TrEMBL)
p-Y705-STAT3 dimerComplexR-HSA-1112525 (Reactome)
p-Y705-STAT3 dimerComplexR-HSA-1112526 (Reactome)
p-Y705-STAT3ProteinP40763 (Uniprot-TrEMBL)
p-Y986,Y1079,Y1141-LEPR-1 ProteinP48357-1 (Uniprot-TrEMBL)

Annotated Interactions

View all...
SourceTargetTypeDatabase referenceComment
ADPArrowR-HSA-2586553 (Reactome)
ADPArrowR-HSA-2586555 (Reactome)
ADPArrowR-HSA-2671742 (Reactome)
ADPArrowR-HSA-2671829 (Reactome)
ADPArrowR-HSA-2671850 (Reactome)
ADPArrowR-HSA-2671862 (Reactome)
ATPR-HSA-2586553 (Reactome)
ATPR-HSA-2586555 (Reactome)
ATPR-HSA-2671742 (Reactome)
ATPR-HSA-2671829 (Reactome)
ATPR-HSA-2671850 (Reactome)
ATPR-HSA-2671862 (Reactome)
IRS1,2R-HSA-2671873 (Reactome)
LEP:LEPR:JAK2ArrowR-HSA-2586559 (Reactome)
LEP:LEPR:JAK2R-HSA-2586555 (Reactome)
LEP:LEPR:JAK2mim-catalysisR-HSA-2586555 (Reactome)
LEP:LEPR:p-JAK2ArrowR-HSA-2586555 (Reactome)
LEP:LEPR:p-JAK2R-HSA-2586553 (Reactome)
LEP:LEPR:p-JAK2mim-catalysisR-HSA-2586553 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1:IRS1,2ArrowR-HSA-2671873 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1:IRS1,2R-HSA-2671862 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1:p-IRS1,2ArrowR-HSA-2671862 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1ArrowR-HSA-2671872 (Reactome)
LEP:p-LEPR:p-JAK2:SH2B1R-HSA-2671873 (Reactome)
LEP:p-LEPR:p-JAK2:SHP2ArrowR-HSA-2671747 (Reactome)
LEP:p-LEPR:p-JAK2:SHP2R-HSA-2671742 (Reactome)
LEP:p-LEPR:p-JAK2:SHP2mim-catalysisR-HSA-2671742 (Reactome)
LEP:p-LEPR:p-JAK2:SOCS3ArrowR-HSA-2672302 (Reactome)
LEP:p-LEPR:p-JAK2:SOCS3TBarR-HSA-2586555 (Reactome)
LEP:p-LEPR:p-JAK2:STAT3ArrowR-HSA-2671868 (Reactome)
LEP:p-LEPR:p-JAK2:STAT3R-HSA-2671850 (Reactome)
LEP:p-LEPR:p-JAK2:STAT3mim-catalysisR-HSA-2671850 (Reactome)
LEP:p-LEPR:p-JAK2:STAT5ArrowR-HSA-2671855 (Reactome)
LEP:p-LEPR:p-JAK2:STAT5R-HSA-2671829 (Reactome)
LEP:p-LEPR:p-JAK2:STAT5mim-catalysisR-HSA-2671829 (Reactome)
LEP:p-LEPR:p-JAK2:p-SHP2ArrowR-HSA-2671742 (Reactome)
LEP:p-LEPR:p-JAK2:p-STAT3ArrowR-HSA-2671850 (Reactome)
LEP:p-LEPR:p-JAK2:p-STAT3R-HSA-2671839 (Reactome)
LEP:p-LEPR:p-JAK2:p-STAT5ArrowR-HSA-2671829 (Reactome)
LEP:p-LEPR:p-JAK2:p-STAT5R-HSA-2671876 (Reactome)
LEP:p-LEPR:p-JAK2ArrowR-HSA-2586553 (Reactome)
LEP:p-LEPR:p-JAK2ArrowR-HSA-2671839 (Reactome)
LEP:p-LEPR:p-JAK2ArrowR-HSA-2671876 (Reactome)
LEP:p-LEPR:p-JAK2R-HSA-2671747 (Reactome)
LEP:p-LEPR:p-JAK2R-HSA-2671855 (Reactome)
LEP:p-LEPR:p-JAK2R-HSA-2671868 (Reactome)
LEP:p-LEPR:p-JAK2R-HSA-2671872 (Reactome)
LEP:p-LEPR:p-JAK2R-HSA-2672302 (Reactome)
LEPR-HSA-2586559 (Reactome)
LEPR:JAK2R-HSA-2586559 (Reactome)
PTPN11R-HSA-2671747 (Reactome)
R-HSA-2586553 (Reactome) Phosphorylated JAK2 phosphorylates the Leptin receptor (LEPR or OB-Rl, long isoform) at multiple tyrosine residues in the C-terminal, cytoplasmic domain (Bjorbaek et al. 1997, White et al. 1997, Ghilardi and Skoda 1997, Carpenter et al. 1998). The phosphotyrosines residues of LEPR then act as docking sites for downstream effectors STAT5, STAT3, SHP2, SH2B1, and SOCS3.
R-HSA-2586555 (Reactome) As inferred from mouse, binding of Leptin (LEP) to the Leptin receptor (LEPR) causes a conformational change in LEPR that activates autophosphorylation of JAK2 at multiple tyrosine residues. Phosphorylated JAK2 has much higher kinase activity than unphosphorylated JAK2.
R-HSA-2586559 (Reactome) Analysis of a structural model of the Leptin-LEPR complex using as a basis the complex formed by granulocyte-colony stimulator factor (GCSF) and its receptor G-CSF R (Hiroike et al., 2000) suggested that helices I and III of the human leptin structure were likely sites of interaction with the cytokine binding domain of leptin receptor (Gonzalez and Leavis, 2003). It is believed that the Leptin receptor (LEPR) is a dimer constitutively bound in a complex with JAK2 kinase (Couturier and Jockers 2003). It has been proposed that one molecule of Leptin binds each monomer of LEPR (Luoh et al. 1997, Mistrik et al. 2004), however these suggestions need further proof becasue the structure of the Leptin:LEPR complex has not yet been solved.
R-HSA-2671742 (Reactome) Phosphorylated JAK2 in the LEP:LEPR:JAK2:SHP2 complex phosphorylates SHP2 (Carpenter et al. 1998). Phosphorylated SHP2, in turn, activates the RAS-MAPK signaling pathway, possibly via GRB2:SOS.
R-HSA-2671747 (Reactome) SHP2 (PTPN11) interacts with phosphotyrosine-986 of the phosphorylated Leptin receptor (LEPR) (Carpenter et al. 1998). The corresponding site in mouse is phosphotyrosine-985 and in rat phosphotyrosine-986.
SHP2 and SOCS3 compete for the same binding site on LEPR. SHP2 activates MAPK signaling, probably by recruiting GRB2:SOS which activates RAS.
R-HSA-2671829 (Reactome) Phosphorylated JAK2 phosphorylates STAT5 (at phosphotyrosine-694 of STAT5A and probably at the homologous residue in STAT5B) while STAT5 and JAK2 are bound to LEPR (Briscoe et al. 2001).
R-HSA-2671839 (Reactome) Phosphorylated STAT3 dissociates from LEPR in the LEP:LEPR:JAK2 complex, dimerizes, and translocates to the nucleus.
R-HSA-2671850 (Reactome) Phosphorylated JAK2 in the LEP:LEPR:JAK2:STAT3 complex phosphorylates STAT3 at tyrosine-705 (Bjorbaek et al. 1997).
R-HSA-2671855 (Reactome) STAT5 interacts with phosphotyrosine-1079 of LEPR in the LEP:LEPR:JAK2 complex, bringing STAT5 in proximity to the JAK2 kinase (Briscoe et al. 2001).
R-HSA-2671862 (Reactome) JAK2 phosphorylates IRS1/2 after IRS1/2 binds SH2B1 in the LEP:LEPR:JAK2:SH2B1 complex (Martin-Romero and Sanchez-Margalet 2001, Li et al. 2007). However, in some cells leptin may only affect phosphorylation of IRS1/2 when insulin signaling subsequently occurs (Szanto and Kahn 2000). As inferred from mouse and rat (Buettner et al. 2008, Hill et al. 2008) phosphorylated IRS1/2 then activates PI3K independently of STAT3 signaling.
R-HSA-2671868 (Reactome) STAT3 binds phosphotyrosine-1141 of the C-terminal, cytoplasmic region of LEPR (Bjorbaek et al. 1997). Only the long isoform of LEPR has tyrosine-1141 and consequently only the long isoform of LEPR activates STAT3. Short isoforms of LEPR exist but their function is uncertain. Shorter LEPR isoforms bind JAK2 and can signal through IRS-1 or ERKs, including MAPKs (Bjorbaek et al. 1997).
R-HSA-2671872 (Reactome) The SH2 domain of SH2B1 binds phosphotyrosine-813 of JAK2 (Nishi et al. 2005, Li et al. 2007). Binding of SH2B1 to JAK2 enhances leptin-induced JAK2 activity. SH2B1 also recruits IRS1 for phosphorylation by JAK2 (Li et al. 2007).
R-HSA-2671873 (Reactome) SH2B1 in the LEP:LEPR:JAK2:SH2B1 complex can bind either IRS1 or IRS2 (Duan et al. 2004, Li et al. 2007). The binding brings IRS1/2 into proximity with JAK2 for phosphorylation.
R-HSA-2671876 (Reactome) Phosphorylated STAT5 dissociates from LEPR, dimerizes, and then translocates to the nucleus.
R-HSA-2672302 (Reactome) As inferred from mouse, SOCS3 binds LEPR at phosphotyrosine-986 and phosphotyrosine-1079. SOCS3 competes with SHP2 (PTPN11) for phosphotyrosine-986 and with STAT5 for phosphotyrosine-1079. SOCS3 expression is upregulated by leptin and SOCS3 downregulates prolonged leptin signaling, providing a feedback loop to limit leptin's action.
R-HSA-2730595 (Reactome) As inferred from mouse, both non-phosphorylated and phosphorylated STAT3 can form dimers and enter the nucleus. Phosphorylation of STAT3 appears to change the equilibrium between these states, causing accumulation of phosphorylated STAT3 in the nucleus. Phosphorylated STAT3 dimers also activate transcription more efficiently.
R-HSA-2730599 (Reactome) As inferred from mouse, both non-phosphorylated and phosphorylated STAT3 are imported and exported from the nucleus. Phosphorylation shifts the equilibrium distribution of STAT3 to the nucleus.
R-HSA-452102 (Reactome) Phosphorylated STAT5A and STAT5B form homodimers and heterodimers in the cytosol (Gaffen et al. 1996, Rosenthal et al. 1997, also inferred from mouse homologs). Phosphorylation of a critical tyrosine residue in the SH domain (Y694 in STAT5A and Y699 in STAT5B) and intramolecular interactions between hydrophobic residues in the SH domain are required for dimerization (inferred from mouse homologs).
R-HSA-507937 (Reactome) Interleukin-7 (IL7)-activated Signal transducer and activator of transcription 5A or 5B (typically referred to as STAT5) is recruited rapidly to the promoters of IL7-regulated genes (Ye et al. 2001, Stanton & Brodeur 2005).
SH2B1-2R-HSA-2671872 (Reactome)
SOCS3R-HSA-2672302 (Reactome)
STAT3R-HSA-2671868 (Reactome)
STAT5A,STAT5BR-HSA-2671855 (Reactome)
p-STAT5 dimerArrowR-HSA-452102 (Reactome)
p-STAT5 dimerArrowR-HSA-507937 (Reactome)
p-STAT5 dimerR-HSA-507937 (Reactome)
p-STAT5A, p-STAT5BArrowR-HSA-2671876 (Reactome)
p-STAT5A, p-STAT5BR-HSA-452102 (Reactome)
p-Y705-STAT3 dimerArrowR-HSA-2730595 (Reactome)
p-Y705-STAT3 dimerArrowR-HSA-2730599 (Reactome)
p-Y705-STAT3 dimerR-HSA-2730599 (Reactome)
p-Y705-STAT3ArrowR-HSA-2671839 (Reactome)
p-Y705-STAT3R-HSA-2730595 (Reactome)
Personal tools